MODIF-MS: ifenprodil study with conflicting status records
Published by MyelinWatch:
MODIF-MS · MODIF-MS is a Phase 1/2 study testing ifenprodil, which changes signalling through NMDA receptors, in people with multiple sclerosis.
What is being studied
MODIF-MS is a Phase 1/2 study testing ifenprodil, which changes signalling through NMDA receptors, in people with multiple sclerosis.
Research stage
Phase 1/2 study evidence; current programme status is unknown
Current programme and human-study status are unknown.
What we know so far
The CTIS summary lists a temporary halt, while site-level information has indicated that the study may still be accepting participants. I could not independently confirm the current CTIS details; no result establishing benefit is available, and a possible restart is unconfirmed.
What this means for patients today
The conflicting records do not confirm whether the study is accepting participants now. Ifenprodil is not an established MS treatment.
- Treatment or approach
- Ifenprodil • possible myelin repair
- How it is intended to work
- Uses ifenprodil to change signalling through NMDA receptors
- Where the study is running
- Centres in France • none in Greece
- Published by MyelinWatch
- Last substantive MyelinWatch update